asco.org5d
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org8d
Pharmacokinetics (PK) of epacadostat in combination with sirolimus in advanced malignancy.
1 < LLOQ 769 (93.6-1610) N=5 145 (33.1-257) N=2 1016 (922-1110) N=2 ...
asco.org8d
A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org9d
A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org9d
Outcomes of an innovative six-week standardized residential training course for physicians and nurses to provide primary palliative care in India.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org8d
Expression of PD-L1 and IDO in hormone receptor negative DCIS.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org12d
Recommendations to Reduce Out-of-Pocket Costs for People with Cancer Detailed in New ASCO Position Statemen
The American Society of Clinical Oncology (ASCO) released a new position statement today detailing recommendations for health care stakeholders to reduce the heavy financial burden people with cancer ...
asco.org12d
Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
N (%) OS: HR (95% CI, p-value) PFS: HR (95% CI, p-value) ORR: OR (95% CI, p-value) ...
asco.org12d
Post-registration experience of nivolumab (nivo) therapy in patients with advanced hepatocellular carcinoma (HCC): An international study.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org8d
T-cell redirected bispecific antibodies in relapsed and refractory multiple myeloma: A systematic review and meta-analysis.
NR- not reported NR*- not reached Clinical outcome data with use of bispecific antibodies.
asco.org12d
Optimization of an imaging protocol for stage I seminoma surveillance based on variations in relapse location over time.
Time and location of relapse.
asco.org13d
New Reports Assess Oncology Workforce Well-being, Propose Solutions to Address Burnout
Physician burnout has increased significantly in the last decade and organizational strategies are vital to improve physician well-being, according to new research from the American Society of ...